Trial Profile
A Randomized, Double-blind, Multicenter Study to Evaluate the Efficacy and Safety of ALX 0171 Versus Placebo, in Addition to Standard of Care, in Adults Who Have Undergone Hematopoietic Stem Cell Transplantation and Present With a Respiratory Syncytial Virus Respiratory Tract Infection
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 29 Mar 2023
Price :
$35
*
At a glance
- Drugs Gontivimab (Primary)
- Indications Respiratory syncytial virus infections
- Focus Therapeutic Use
- Sponsors Ablynx
- 10 Jul 2020 This trial has been Discontinued in Belgium according to European Clinical Trials Database record.
- 08 Mar 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 16 Feb 2019 This trial has been discontinued in Germany and Italy.